Thomas Dilling, MD, MS, FASTRO

Moffitt Cancer Center
Tampa, FL, United States

Dr. Dillings primary clinical focus is the radiotherapeutic treatment of thoracic malignancies. His research interests focus on the use of Big Data and machine learning techniques to predict clinical outcomes.

Disclosures:

• Employment: Moffitt Cancer Center:Senior Member:Employee
• Compensation: AstraZeneca: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Consultant, Honoraria-End Date: ongoing
• Ownership: none
• Leadership: NCCN:NSCLC, meso, and thymoma tx guideline committees

Presentation(s):

• 2031 - Role of Whole-Heart Dose on Overall Survival (OS) in Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Patients (Pts) Treated with Concurrent Definitive Chemoradiotherapy (CDCRT)

  Sunday, September 29, 2024
  2:45 PM – 4:15 PM ET

• 2032 - Role of Cardiac Sub-Structure (CSS) Dose on Overall Survival (OS) in Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Patients (Pts) Treated with Concurrent Definitive Chemoradiotherapy (CDCRT)

  Sunday, September 29, 2024
  2:45 PM – 4:15 PM ET

• SS 16 - Lung 3: Clinical Trials of Chemoradioimmunotherapy and Risk Adapted Radiotherapy for Advanced Lung Cancer

  Monday, September 30, 2024
  10:45 AM – 12:00 PM ET